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Heart Valve Surgery at Henry Ford Hospital
from a Perspective of Thirty-Two Years

This issue of the Henry Ford Hospital Medical Journal
contains eight papers on the subject of the porcine bioprosthetic heart valve. It is now 32 years since the first
heart valve operation, a mitral commissurotomy, was
performed at Henry Ford Hospital. The operation was
carried out in spite of the rather vigorous opposition of
the chief of cardiology. W h e n 12 cases of mitral commissurotomy with three deaths were reported to the Detroit
Academy of M e d i c i n e , a discussant w h o had done some
rapid calculation said that he could not say anything
favorable about an operation which had a 25% mortality
rate. He was not impressed with the rebuttal argument
that the valves of those w h o had not survived were
hopelessly deformed and the problem was more that of
insufficiency than stenosis. Nothing but replacement
with new valves would have been curative.

mechanism in the valve and by listening for the cracking
of the calcified tissue, one could be sure that the valve
had been opened to some extent.
Before the pump-oxygenator became available, brief
" o p e n heart" operations were done under hypothermia
or simply by means of caval occlusion. There was ample
time to make three cuts in the pulmonary valve, but the
same technique applied to the aortic valve was not successful. The remark was often heard that " W e need a
new valve."
A pump-oxygenator of the DeWall-Lillehei bubble type
was first used at Henry Ford Hospital in A p r i l , 1956. First
priority was given to operations on children with congenital heart disease, especially those with ventricular
septal defects, because many were threatened with irreversible pulmonary hypertension. But before long, open
operations for mitral and aortic stenosis began to replace
the closed procedures. In 1958, there were 118 mitral
commissurotomies, and all but two were by the " o l d fashioned" closed technique. In 1964, of 88 operations,
55-60% were done under direct vision. W h e n the problem with the valves was mainly stenotic, these operations
were nearly all successful. But until prosthetic replacement became available, there was no real solution to the
problem of mitral insufficiency.

Mitral commissurotomy rapidly became a respectable
operation in the early 1950s. It was never called " b l i n d
surgery" by those w h o did it but rather a procedure
under "digital vision." Modifications of the technique of
Dr. Charles P. Bailey and his associates became available,
but undoubtedly the improvement in results was due
more to the accumulation of surgical experience. At
Henry Ford Hospital, troublesome bleeding around the
commissurotomy knife was eliminated by Dr. Edward
Munnell's development of a six-fingered glove, the
knife passing through the sixth finger to which a ligature
could be applied. During the early operations, the pressure changes in the left auricle were displayed and
recorded by the Hathaway impedance gauging system.
The presence of unsuspected significant mitral insufficiency, so evident to the surgeon's finger, could be
graphically recorded.

W i t h the adequate operating time provided by extracorporeal circulation, it was at least possible to perform a
more cosmetic repair of the stenosed or leaking aortic
valve. A few cases of insufficiency were corrected by
suturing the cusps to make a bicuspid valve. Commissures (if present) could be cut under direct vision, and
calcified plaques could be removed. We even used a
high speed dental drill for decalcification! During a
three-year period from 1962 to 1965, the drill was used in
75 operations for calcific aortic stenosis. In 56, the valve
leaflets were d e b r i d e d , and in 19 operations the calcified
aortic annulus was prepared to receive a prosthesis.

It was hoped that a similar operation w o u l d be able to
separate the fused cusps in aortic stenosis. Since it was
obviously impractical to approach theaortic valve with a
finger through the wall of the left ventricle. Bailey developed a transaortic operation, with the forefinger passing
through a cloth tunnel sutured to an opening in the
aorta. A l t h o u g h I tried this operation several times, I
never had good results. Mainly, I was impressed with the
rigidity of the fibrosed and calcified valves. M o r e consistent results were obtained with the Bailey aortic dilator, an instrument passed into the valve via the left ventricle. By vigorously squeezing the handle to expand the

The first caged ball valve was placed in the aortic position by Dr. Dwight Harken in 1960. The lucite poppet in
his prosthesis was noisy, and there was more interest in
theStarr-Edwards valve, which had a silicone rubber ball
(1962). The obvious disadvantage o f t h e spherical poppet
was that it tended to obstruct the flow of blood. The
170
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Smeloff-Cutter valve in the mitral position produced less
obstruction, since, in systole, half of the poppet was back
in the auricle. Numerous valves with disc poppets soon
appeared on the market, but they all carried the same
danger of thrombosis and embolism as the ball valves.

countries, while human homografts were reasonably
available. The result of this situation was the early work
of Duran and Ross in England and of Barratt-Boyes in
New Zealand, now of Australia.
No homograft was ever used in a human being at Henry
Ford Hospital. But in 1971, Dr. Julio C. Davila began to
use grafts f r o m a lowly animal, the pig, to replace aortic
and mitral valves. Dr. Donald J. Magilligan's article on
the "Natural History of the Porcine Bioprosthetic Heart
Valve" describes the developments of this decade at
Henry Ford Hospital. Experience with these "gluteraldehyde-stabilized porcine xenografts" or " p o r c i n e bioprosthetic heart valves" constitutes the basis of the lead
articles in this issue of our Journal.

In 1950, Drs. Aram, M u n n e l l , and 1 performed some
animal experiments in the surgical laboratory at Henry
Ford Hospital on aortic valve homografts. Since we had
no heart-lung apparatus that w o u l d allow us to place the
grafts in the subcoronary position, we inserted them in
the descending aorta. The cusps deteriorated rapidly
unless aortic insufficiency was produced in the recipient
animal by the destruction o f o n e cusp. The grafted valve
continued to function until the host's valve became
competent by adaptation of the two undamaged cusps.
There was a surprising amount of interest in our work
abroad, especially in England and New Zealand. A m e r i can prosthetic valves were prohibitively costly in those

Conrad R. Lam, M D
Consultant, Department of Surgery,
Division of Thoracic Surgery
Henry Ford Hospital

A Challenge to Physicians: The Obligation and Ultimate Reward
We live in intensely troubled times. Widespread social
dislocations, economic disarray, and nuclear destruction threaten to disrupt our lives. These anxieties, and
the intermittent rewards and joys, if not experienced
directly, come through unrelenting communications of
one sort oranother. W h e t h e r t h e individual mission bea
labor of economic survival, the pursuit of creative work,
or the search for identity, we cannot escape transmitted
words and images issuing from a host of authorities,
assumed experts, analysts, and interpreters. The mounting problems are more than matched by a legion of
answers, and the field of medicine is no exception. Public controversies about the objectives, structure, control,
service distribution, and financing in medicine create
dilemmas of purpose and direction for many physicians.

for more humanism in the language of medicine and,
ultimately, in the actions of medicine. In a profession so
infiltrated by the jargon of the business w o r l d , who can
take issue with this appeal f r o m a scholar of medical and
health affairs?
Apart f r o m the messages themselves, the fact that they
have not come from within our o w n profession indicates
perhaps either a timidity by physicians or a preoccupation with the pressing affairs of today. For another controversial issue, one of horrendous implications and
affecting all humanity, physicians have been aroused
and responsive, as witnessed by the widely acclaimed
efforts of Physicians For Social Responsibility and the
recently published book. The Final Epidemic — Physicians and Scientists on Nuclear War (4). Why have these
socially concerned physicians not spoken out for the
issues identified by Schwartz and Fein, both so vital to
the integrity of the medical profession and our national
welfare? O n e might ask, also, why it is that the existing
agencies within organized medicine have not similarly
responded? Answers may be f o u n d in an understanding
of the diversity which characterizes the centers of philosophic and policy formulations with the medical w o r l d .

In my reflections on these controversies, two recently
published articles keep coming to m i n d . Though of different themes, both havesubstantial implicationsforthe
practice of medicine. The first article is by Harry Schwartz,
published in Newsweek (1), with a later version in The
New York Times (2). The second is the Sounding Board
communication of Rashi Fein in the New England Journal of Medicine (3). Schwartz addresses the ever-growing,
already staggering costs of medical care, and he foretells
some punishing debates on the principles of how we will
(not whether we should) ration its services. For physicians, no less than for the nation at large, this is a profoundly disturbing scenario by a university writer-inresidence. Juxtaposed in my mind is Fein's timely appeal

First, it should be acknowledged that physicians are
addressing the cost issue by voluntary restraints in practice, by policies and procedures adopted by hospital
staffs, local medical societies, specialty groups and
national associations, and by principles and goals pro171

Editorials

vided by the Instituteof Medicine (National Academy of
Sciences). But these sincere efforts have been blunted
by countervailing forces, both economic and political,
beyond the domain of the medical care " i n d u s t r y " .
Although commonly so charaaerized, the medical profession is not, in fact, organized. It is an assortment of
specialty "cartels", loosely aligned through various colleges and councils that exist primarily and understandably to define areas of responsibility and for accrediting
and educational purposes. Quite properly, the American Medical Association "has officially reaffirmed that
national representation of the medical profession is its
most prominent f u n c t i o n . " Yet it is compromised, since
nearly one-half of the nation's physicians, many of
w h o m hold more progressive views, are not members of
the A M A . O u r medical schools and research establishments, with superb resources generated by governmental largesse and generous philanthropic support of the
last several decades, are not in a mood for containment.
O n e result, quite unintentional, is an upward push on
already costly health services. Nor is it likely that universities and community hospitals, for reasons of prestige
and politics, will significantly reduce the upward trend
by moderating their acquisition of the latest sophisticated services. Despite its ambivalence about physician
needs and its need to protect hospital interests, the
American Hospital Association has nonetheless sponsored cost-containment procedures. These measures
have had but limited success.

be a means of l i v e l i h o o d " (5). Today's physician, whatever his or her environment, should constantly strive for
that goal. The economic burden of American medicine
is at the limit of tolerance, and time is running out for the
prevailing order. M o r e aggressive countermeasures are
being generated by those w h o hold the purse strings.
The need for physicians is clear — to seek collectively an
overall reordering of values and goals and to d o so with
the same passion and persuasion as the Physicians for
Social Responsibility seek nuclear disarmament. If physicians take this initiative, they could establish a new
base of professionalism. They could reawaken the awareness that our primary obligation as physicians is to heal,
comfort, and prevent, not to do business. No one said it
better than Sir William Osier in his 1903 address. The
Master-Word in Medicine (6):
" M o r e than any other, the practitioner of medicine may illustrate the second great lesson, that
we are here not to get all we can out of life for
ourselves, but to try to make the lives of others
happier. This is the essence of the oft-repeated
admonition of Christ: 'He that findeth his life
shall lose it, and he that loseth his life for my sake
shall find it'; on which hard saying, if the children of this generation w o u l d lay hold, there
w o u l d be less misery and discontent in the
w o r l d . It is not possible for anyone to have better opportunities to live this lesson than you will
enjoy. The practice of medicine is an art, not a
trade; a calling, nota business; a calling in which
your heart will be exercised equally with your

Whatever the approach to the issue of cost containment,
the physician as the primary provider bears a great
responsibility. Are we so involved in our businesses and
in our various professional organizations that a union of
concerned physicians cannot emerge and boldly take up
Schwartz's editorial challenges? Do we have too much to
lose in a society dominated by an economic raison
d'etre? Must the whole social order change before medicine changes?

head."
The challenge is there. Will we meet it and, in so d o i n g ,
find our ultimate reward?
Richmond W. Smith, Jr, M D *
Tenant's Harbor, Maine

Forty years ago Roscoe Pound, then Dean of the Harvard
Law School, defined professionalism as a "pursuit of a
c o m m o n calling as a learned art and asa public service —
nonetheless a public service because it may incidentally

Dr. Smith is the former Chairman of the Department of Internal Medicine and
past Chairman of the Council of Department Chairmen at Henry Ford Hospital.
He retired from the Hospital in 1980 and lives in Tenant's Harbor, Maine.
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The Beta Blocker Heart Attack Trial: At Last,
An Effective Medical Therapy to Prevent Death from Coronary Heart Disease

In the last two decades major advances have occurred in
our understanding and treatment of coronary heart disease, in particular for those individuals w h o have experienced acute myocardial infarction. Most recently, it
has been demonstrated that beta adrenergic blocking
agents can lower the mortality rate after such an event
(1,2). Before the mid-twentieth century, this disease was
merely a subject of interest to the morbid anatomist.
Now, the expansion of our scientific knowledge has
culminated in identifying an important therapeutic
intervention.

infarction as we reflect on new therapeutic interventions.
The risks of the intervention must be measured against
the risk of the disease itself.
A number of secondary interventions have been proposed in the last two decades for the long-term treatment
of patients following myocardial infarction. O u r understanding ofthese interventions has not been simple, and
many questions still remain. Clinical investigation has
been hampered by our continued ignorance of the
mechanism of ischemia, infarction, and the progression
of coronary arterial disease. The Coronary Drug Project
(4-6) tested a number of medications, including estrogens, clofibrate, thyroid hormone, and niacin, but to no
avail. The early thrust was on anticoagulant therapy and,
more recently, on antiplatelet agents, based on the
assumption that coronary thrombosis represented a
major mechanism of acute myocardial infarction. The
significance of thrombotic events in acute myocardial
infarctions still is not fully understood. Whether it is a
primary event or secondary to coronary arterial narrowing and stasis associated with left ventricular asynergy is
still not entirely clear. Trials with anticoagulant therapy,
and more recently with aspirin (7), have provided less
than clear answers. Although the Aspirin Myocardial
Infarction Study (7), carried out by the National Heart,
Lung, and Blood Institute, demonstrated that aspirin was
ineffective, the persantin-aspirin trial (8), which has
been reorganized, is still investigating the effect of
aspirin and persantin in post-myocardial infarction
patients. The use of sulfinpyrazone (9) has been so badly
clouded by poor experimental design that we probably
will never know whether or not this drug is effective. At
least at present, the data do not indicate significant
effectiveness for any of these agents.

The first advances came when antiarrhythmic therapy
and electronic pacemakers and defibrillators were used
in the setting of the new coronary care units. These
developments focused the attention of the medical
community on acute myocardial infarction with an
intensity that w o u l d have made James Herrick, the first
to describe an acute "heart attack", smile with pride (3).
This focusing of clinical research on acute myocardial
infarction, largely due to the development of the coronary care unit, cannot be underestimated. It permitted
us to describe the patient with acute myocardial infarction more intensely and provided a framework within
which medical and surgical interventions could be
evaluated. The initial emphasis was on the recognition
and treatment of cardiac arrhythmias that occurred in
the early phase of acute myocardial infarction.
The coronary care unit also became the starting point in
the study of the natural history of patients experiencing
an acute myocardial infarction. These patients provide
us with an important glimpse of the vast problems of
individuals in our society suffering from coronary heart
disease. As our knowledge expanded, we realized that
patients with acute myocardial infarction represent a
heterogenous g r o u p , many of w h o m are at low risk of
having recurrent infarction and death. Others are at an
increased risk, w i t h a high mortality rate in the first six
months after the event. O n the average, however, the
one-year mortality rate of patients experiencing acute
myocardial infarction is 5-6%, and the two-year mortality
rate is under 10%. I n order to make use o f t h e technological and pharmacological developments that have
occurred in the last two decades, we must understand
the natural history of individuals with acute myocardial

Beg inning about 15 years ago, beta adrenergic blocking
agents began to be tested in post-myocardial infarction
patients. These early studies gave promise without
proof; but as a result the Beta Blocker Heart Attack Trial
(BHAT) (1),which studied p r o p r a n o l o l , and a n u m b e r o f
trials with similar agents were carried out in Europe (2).
These studies all indicate that a significant decrease in
mortality, between 26% and 36%, can be achieved with
these agents. By and large, these trials have been
designed to test the effectiveness o f t h e drug in the latter
173
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phase of acute myocardial infarction, beginning one to
three weeks after the event. These agents not only have
demonstrated a decrease in total mortality, but they
have also been shown to reduce the recurrence of
myocardial infarction. In the l o n g t e r m , the26% decrease
in mortality over a two-year f o l l o w - u p period indicates
that the administration o f t h e s e drugs will result in the
survival of two to three individuals out of 100 treated.
Preliminary analysis indicates that the impact of these
drugs is uniform in all clinical subgroups. The relative
effect is the same, but the impact on the total mortality
rate is greater in those at high risk. Those with multiple
infarction, those with complicated in-hospital courses,
those individuals w h o are older — all have a higher
mortality rate; therefore, the 26% decrease in mortality
achieved by beta blockade results in greater numbers of
individuals being saved.

long-term mortality in coronary heart disease is not
clear. At present, it appears that the drug therapy should
be continued for at least three years after an acute
myocardial infarction.
The remarkable achievement of the beta adrenergic
blocking story is a culmination of many years of research
in the coronary care units and basic research laboratories around the w o r l d . This research has led to our better
understanding of acute myocardial infarction. Nevertheless, it is important to realize that only a small fraction
of patients survive to reach the hospital and that 60% of
the deaths in coronary heart disease are sudden and
occur long before the individual reaches the coronary
care unit. The identification of the patient with acute
myocardial infarction is the first step in interdicting the
sudden death process. The administration of beta blockers
to patients after a myocardial infarction reduces not only
total mortality but also the risk of sudden cardiac death.

Nevertheless, the results of these trials indicate with a
clarity rarely observed in medical research that beta
blocking agents should be administered to all individuals after acute myocardial infarction excluding those
for w h o m they are cont rai ndicated, such as patients with
chronic lung disease, bradycardia, hypotension, or severe
congestive heart failure.

These recent successes are clouded by the realization
that our knowledge about the development and progression of coronary heart disease remains catastrophically limited. Hopefully, in the future, we will be able to
prevent this disease successfully. For the present, however, we have an o p p o r t u n i t y to offer our patients w h o
have experienced a recent myocardial infarction an
effective means of preventing recurrent cardiac events.

How long to continue therapy remains unanswered. The
BHAT results indicate that a positive effect was observed
throughout the three years of follow-up. Whether or not
long-term administration may be associated with adverse
effects is not k n o w n . Preliminary data suggest that these
agents may have an adverse effect on triglycerides and
high density lipid cholesterol, although this effect on

Sidney Goldstein, M D
Division Head, Cardiovascular M e d i c i n e
Department of Internal M e d i c i n e
Henry Ford Hospital

References
Beta Blocker Heart Attack Trial Research G r o u p . A randomized
trial of propranolol in patients with acute myocardial infarction.
J A M A 1982;247:1707-14.

5. The Coronary Drug Project Research G r o u p. Clofibrate and niacin
in coronary heart disease. JAMA 1975:231:360.
6. The Coronary Drug Project Research G r o u p . Findings leading to
further modifications of its p r o t o c o l w i t h respect t o d e x t r o t h y r o x ine. JAMA1972;220:996.

The Norwegian Multicenter Study G r o u p . T i m o l o l - i n d u c e d reduct i o n in mortality and reinfarction in patients surviving acute
myocardial infarction. N Engl J M e d 1981 ;304:801-7.

7. Aspirin Myocardial Infarction Study Research G r o u p . A r a n d o m ized c o n t r o l l e d trial of persons recovered f r o m myocardial infarction. JAMA 1980:243:66.

Herrick JB. Clinical features of sudden obstruction of the coronary
arteries. JAMA 1912:59:2015.
The Coronary Drug Project Research G r o u p . Findings leading to
d i s c o n t i n u a t i o n of the 2.5 m g / d a y estrogen g r o u p . J A M A
1973:266:652.

8. The Persantine Aspirin ReinfarctionTrial Research G r o u p . Persantine and aspirin in coronary heartdisease. Circulation 1980;62:449.
9. The A n t u r a n e Reinfarction Trial Research G r o u p . Sulfinpyrazone
in the prevention of sudden death after myocardial infarction. N
Engl J M e d 1980;302:250.

174

Non-Profit O r g .
U.S. Postage
PAID
Detroit. M i r h .
Permit No. 6785

Detroit, Michigan 48202
Address correction requested.
Forwarding and return postage guaranteed.

Observations Suggesting a Possible Link
Between Gammacarboxyglutamic Acid and
Porcine Bioprosthetic Valve Calcification
Joseph A. Helpern, MA
Stephen J. McGee, MS
Jeanne M. Riddle, PhD

152

SPECIAL ARTICLE
The Surgeon and the Patient with Cancer:
The Development of Surgical Oncology
Angelos A. Kambouris, MD

156

•<
O

160

Jerome R. Waldbaum, MD
William T. Beher, PhD
Robert J. Priest, MD
Sofia Stradnieks
Medical Grand Rounds: O p e n and Closed
Loop Insulin Delivery Systems in Diabetes:
Current Status

OJ

o

CLINICAL ARTICLES
Preliminary Report: Effects of Tetracycline
o n Fecal Bile Acid Pool Composition
in a Human

<
g_

Z

TO
-T-l

o
•
163

O

F. John Service, MD, PhD
Clinical Note: Use of Clonidine to Detoxify
Opiate-Addicted Patients
Dennis L. Caffrey,
Tai P. Yoo, MD

168

MD

a
n
>

EDITORIALS

I—

Heart Valve Surgery at Henry Ford Hospital
f r o m a Perspective of 32 Years
Conrad R. Lam, MD
A Challenge to Physicians: The Obligation
and Ultimate Reward
Richmond

2
m

170

TO

171

W. Smith, jr, MD

The Beta Blocker Heart Attack Trial: An
Effective Medical Therapy to Prevent Death
f r o m Coronary Heart Disease
Sidney Goldstein,

MD

O
c

IX)
03
INJ

173

